Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2020

Table of Content

1. Report Introduction

2. Immune Checkpoints Activators
2.1. Immune Checkpoints Activators Overview
2.2. Immune Checkpoints Activators Types
2.3. Immune Checkpoints Activators Structure
2.4. Immune Checkpoints Activators Mechanism of Action
2.5. Immune Checkpoints Activators Application

3. Competitive Landscape

4. Immune Checkpoints Activators - DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Immune Checkpoints Activators Companies Collaborations, Licensing, Acquisition – Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Immune Checkpoints Activators Collaboration Deals
4.1.2.1. Company–Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Company–University Collaborations (Licensing/Partnering) Analysis
4.1.2.3. Immune Checkpoints Activators Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Stage of Development
5.1.2. Assessment by Product Type (Mono/Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Pipeline Therapeutics
6.1. Comparative Analysis

7. Late-Stage Products (Phase-III)

8. Mid-Stage Products (Phase-II)

9. Early-Stage Products (Phase-I)

10. Preclinical and Discovery Stage Products

11. Immune Checkpoints Activators Emerging Drug Profiles
11.1. NKTR-214: Nektar Therapeutics
11.1.1. Product Description
11.1.2. Research and Development
11.1.2.1. Clinical Studies
11.1.3. Product Development Activities
11.1.4. Tabulated Product Summary
11.1.4.1. General Description Table
Many more drugs with detailed profiles provided in the report ?

12. Immune Checkpoints Activators Key Companies

13. Immune Checkpoints Activators Key Products

14. Inactive Products
14.1. Dormant Products
14.1.1. Reason for Dormancy
14.2. Discontinued Products
14.2.1. Reason for Discontinuation

15. Immune Checkpoints Activators - Unmet Needs

16. Immune Checkpoints Activators - Future Perspectives and Conclusion

17. Immune Checkpoints Activators Analyst Views

18. Appendix

19. Report Methodology
19.1. Secondary Research
19.2. Expert Panel Validation

List of Figures

Figure 1 Immune Checkpoints Activators Structure
Figure 2 Immune Checkpoints Activators Mechanism
Figure 3 Immune Checkpoints Activators Types
Figure 4 Immune Checkpoints Activators Clinical Significance
Figure 5 Immune Checkpoints Activators companies collaborations, Licensing, Acquisition – Deal Value Trends
Figure 6 Company–Company Collaborations (Licensing/Partnering) Analysis
Figure 7 Immune Checkpoints Activators Acquisition Analysis
Figure 8 Assessment by Phase of Development
Figure 9 Assessment by Product Type (Mono/Combination)
Figure 10 Assessment by Stage and Product Type
Figure 11 Assessment by Route of Administration
Figure 12 Assessment by Stage and Route of Administration
Figure 13 Assessment by Molecule Type
Figure 14 Assessment by Stage and Molecule Type
Figure 15 Assessment by MOA
Figure 16 Assessment by Stage and MOA
Figure 17 Late-Stage Products (Phase-III)
Figure 18 Mid-Stage Products (Phase-II)
Figure 19 Early-Stage Products (Phase-I)
Figure 20 Preclinical and Discovery Stage Products
Figure 21 Inactive Products
Figure 22 Dormant Products
Figure 23 Discontinued Products
Figure 24 Unmet Needs

List of Tables

Table 1 Assessment Summary
Table 2 Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3 Immune Checkpoints Activators Acquisition Analysis
Table 4 Assessment by Phase of Development
Table 5 Assessment by Product Type (Mono/Combination)
Table 6 Assessment by Stage and Product Type
Table 7 Assessment by Route of Administration
Table 8 Assessment by Stage and Route of Administration
Table 9 Assessment by Molecule Type
Table 10 Assessment by Stage and Molecule Type
Table 11 Assessment by MOA
Table 12 Assessment by Stage and MOA
Table 13 Assessment by Target
Table 14 Assessment by Stage and Target
Table 15 Late-Stage Products (Phase-III)
Table 16 Mid-Stage Products (Phase-II)
Table 17 Early-Stage Products (Phase-I)
Table 18 Preclinical and Discovery Stage Products
Table 19 Inactive Products
Table 20 Dormant Products
Table 21 Discontinued Products